## Journal of Shabwah University

المعنى فليوة

S Journal of Strathard University for Humanities and Provide Strathard University for Humanities

- All Start

dalu

### for Humanities and Applied Sciences

Volume 3 Issue 1 June 2025

(A Biannual Refereed Scientific Periodical)

ISSN 3006-7547 (Print) ISSN 3006-7553 (Online)

Republic of Yemen - Shabwah - Shabwah University



## Antimicrobial Resistance in Wadi Hadramout: A Study on Prevalence and Patterns (2022-2023)

Dr. Ruwais Mohsen Binlaksar

College of medicine and health sciences, Seiyun University (COMAHS) binlaksar2012@hotmail.com

Somia Binlaksar

Menwa Aljabri Medical students at COMAHS Asma Binhatem

#### Abstract

Background: Antimicrobial resistance is a global problem which threatens the public health. New resistance patterns emerge daily, getting through the international boundaries and spreading fast.

Aim: To determine the prevalence of antimicrobial resistance of pathogenic bacteria isolated from clinical samples in Wadi Hadramout, Yemen.

Methodology: A cross-sectional study was carried out in Wadi Hadramout estimating the prevalence of antimicrobial resistance. The clinical samples collected in the period from June 2022 to June 2023 and positive cultures were tested for antimicrobial sensitivity by standard culturing methods and sensitivity toward various antimicrobials. Results: A total of 552 samples (vaginal swab 197, midstream urine142, wound swab124, and others) were collected. The most common pathogens isolated were Staphylococcus aureus 206 (37.3%), Escherichia coli (E coli) 152(27.5%), Pseudomonas aeruginosa 74 (13.4%) and Klebsiella spp 61(11.1%). Staphylococcus aureus had 100% resistance to Amoxycillin, penicillin, and erythromycin with an average of 72% resistance to all tested antibiotics. E coli had 100% resistance to Amoxycillin, penicillin, cefadroxil, and erythromycin, and 94 % to Clarithromycin, Cefixime, Cefalexin, Cefuroxime, trimethoprim, Ceftriaxone, and Vancomycin, with an average resistance of 73% to all tested antibiotics.

Paper Information Received: 22/01/2025 Accepted: 03/02/2025 Issued: 08/07/2025

Keywords antimicrobial resistance, bacteria, staphylococcus aureus, Escherichia coli, wadi Hadramout

Conclusion: the prevalence of antibiotic resistance is very high in Wadi Hadramout, and it seems higher than in the other cities in Yemen.

#### Introduction:

Antimicrobial Resistance (AMR) threatens the public health worldwide. New resistance patterns emerge daily, getting through international boundaries and spreading fast (Abushaheen et al., 2020; Baekkeskov et al., 2020). The global number of Hospital-Associated Infections (HARIs) was estimated to be 136 million per year (Balasubramanian et al., 2023), and about 4.95 million were associated with AMR bacteria in 2019 (Murray et al., 2022). Deaths associated with the 33 bacterial pathogens were estimated to comprise 13.6% of all global deaths and 56.2% of all sepsis-related deaths in 2019. Almost half of which is due to the leading pathogens, mainly Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Streptococcus pneumoniae, and Pseudomonas aeruginosa (Ikuta et al., 2022). Low- and middle-income countries (LMICs) have poor antimicrobial stewardship. And in most of those countries, over-the-counter sales of antibiotics are the norm rather than the exception. Patients from LMICs are exposed to healthcare-associated infections at least 2-fold higher than in high-income countries (HICs) (Balasubramanian et al., 2023). AMR was studied in different regions in Yemen whose findings were: in Aden, 40-80 % (ALhlale et al., 2020; Almehdar et al., 2024; Badulla et al., 2020; Orubu et al., 2021), in Mukalla, 37-70 % (Al-Haddad et al., 2010; Hameed, 2016), in Sanaa, 67-85% (Al-Yosaffi et al., 2023; Edrees &

Anbar, 2021), and in Taiz, 45-85% (Al-Jendy et al., 2018). There is no data about AMR in Wadi Hadramout. This is the first study, to the best of the researchers' knowledge, that aims to investigate the prevalence of AMR in Wadi Hadramout.

#### Methods and materials:

This is a cross-sectional study. The results of the clinical samples tested for bacterial culture and sensitivity were gathered from June 2022 to June 2023 at a private microbiology laboratory database in Seiyun City, Hadramout, Yemen. Results of 552 clinical specimens, which appear to be positive for pathogenic bacteria and tested for antibiotic sensitivity, were included in the study, vaginal swab 197, midstream urine142, wound swab124, and others (Table 1). Standard microbiological methods were applied to identify the bacterial species. The disk diffusion method was used for antimicrobial susceptibility, and the diameter of zone inhibition was measured. Data analysis was performed using Statistical Package for the Social Sciences (SPSS v26). The frequencies of different bacteria and the rate of AMR were calculated. This study did not directly involve human subjects.

#### **Results:**

Five hundred and fifty-two specimens were tested for antibiotic sensitivity. The most common pathogens isolated were *Staphylococcus aureus* 206 (37.3%), *E coli* 152 (27.5%), *Pseudomonas aeruginosa* 74 (13.4%), and *Klebsiella spp*. 61(11.1%), as shown in (Table 1). The results of microbial sensitivity tests revealed that *Staphylococcus aureus* had 100% resistance to Amoxycillin, penicillin, and erythromycin, with an average of 72% resistance to all tested antibiotics, as given in (Fig 1). *E coli* had 100% resistance to Amoxycillin, penicillin, cefadroxil, and erythromycin, and 94% to Clarithromycin, Cefixime, Cefalexin, Cefuroxime, trimethoprim, Ceftriaxone, and Vancomycin, with an average resistance of 73% to all tested antibiotics as shown in (fig 2). *Pseudomonas aeruginosa* had 100% resistance to Amoxycillin, penicillin, Cefadroxil, Piperacillin, trimethoprim, Lincomycin, and erythromycin, with an average resistance of 77% to all tested antibiotics. *Klebsiella spp*. had 100% resistance to Norfloxacin, Cefixime, Lincomycin, Amoxycillin, penicillin, and erythromycin, averaging 73% to all tested antibiotics as presented in (Table 2). Other types of bacteria isolated in smaller numbers with almost the same sensitivity results. Table 1: Types of bacteria and types of specimens

|                            | Type of bacteria AND type of specimen |       |       |        |      |         |        |            |         |          |       |     |  |
|----------------------------|---------------------------------------|-------|-------|--------|------|---------|--------|------------|---------|----------|-------|-----|--|
|                            | type of specimen                      |       |       |        |      |         |        |            |         |          |       |     |  |
| Type of                    | Midstream                             | Wound |       |        | Ear  | Vaginal | Throat | Pus        | Pleural | Synovial |       |     |  |
| bacteria                   | urine                                 | swab  | Semen | Sputum | swab | swab    | swab   | aspiration | fluid   | fluid    | Stool |     |  |
| Escherichia<br>coli        | 60                                    | 14    | 3     | 0      | 0    | 67      | 0      | 4          | 0       | 0        | 4     | 152 |  |
| Staphylococ<br>cus aureus  | 31                                    | 58    | 7     | 1      | 12   | 86      | 0      | 9          | 0       | 2        | 0     | 206 |  |
| Pseudomona<br>s aeruginosa | 11                                    | 37    | 0     | 1      | 5    | 19      | 0      | 1          | 0       | 0        | 0     | 74  |  |
| Klebsiella<br>spp.         | 30                                    | 11    | 2     | 1      | 1    | 11      | 1      | 3          | 0       | 0        | 1     | 61  |  |
| Enterobacte<br>r spp.      | 5                                     | 0     | 0     | 0      | 0    | 12      | 0      | 0          | 0       | 0        | 0     | 17  |  |

OA

| Streptococcu        | 0   | 0   | 0  | 1 | 0  | 0   | 18 | 0  | 1 | 0 | 0 | 20  |
|---------------------|-----|-----|----|---|----|-----|----|----|---|---|---|-----|
| s pyogenes          |     |     |    |   |    |     |    |    |   |   |   |     |
| Proteus spp.        | 5   | 4   | 0  | 0 | 9  | 2   | 0  | 0  | 0 | 0 | 0 | 20  |
| salmonella<br>typhi | 0   | 0   | 0  | 0 | 0  | 0   | 0  | 0  | 0 | 0 | 2 | 2   |
| Total               | 142 | 124 | 12 | 4 | 27 | 197 | 19 | 17 | 1 | 2 | 7 | 552 |

#### Table 2: The Common bacteria isolated and its antibiotic sensitivity results.

| bacteria                    | Staphy                          | lococcus ai                       | ureus         | Escher                          | ichia coli                        |               | Pseudo                          | omonas aer                        | uginosa       | Klebsiella spp.           |                                   |               |  |
|-----------------------------|---------------------------------|-----------------------------------|---------------|---------------------------------|-----------------------------------|---------------|---------------------------------|-----------------------------------|---------------|---------------------------|-----------------------------------|---------------|--|
| Antibiotic                  | Resi<br>stanc<br>e<br>(72<br>%) | Interme<br>diate<br>sensitiv<br>e | sensiti<br>ve | Resi<br>stanc<br>e<br>(73<br>%) | interme<br>diate<br>sensitiv<br>e | sensitiv<br>e | Resi<br>stanc<br>e<br>(77<br>%) | interme<br>diate<br>sensitiv<br>e | sensitiv<br>e | Resi<br>stanc<br>e<br>73% | interme<br>diate<br>sensitiv<br>e | sensitiv<br>e |  |
| Nitrofurantoin              | 79                              | 127                               | 0             | 29                              | 123                               | 0             | 52                              | 22                                | 0             | 39                        | 21                                | 1             |  |
| Norfloxacin                 | 165                             | 40                                | 0             | 83                              | 67                                | 2             | 51                              | 21                                | 0             | 38                        | 23                                | 0             |  |
| Cefixime                    | 201                             | 5                                 | 0             | 148                             | 3                                 | 0             | 73                              | 1                                 | 0             | 60                        | 0                                 | 0             |  |
| Cefalexin                   | 95                              | 11                                | 0             | 78                              | 2                                 | 0             | 46                              | 1                                 | 0             | 39                        | 0                                 | 0             |  |
| Azithromycin                | 178                             | 28                                | 0             | 135                             | 16                                | 1             | 58                              | 15                                | 0             | 49                        | 11                                | 1             |  |
| Co-trimoxazole              | 145                             | 60                                | 1             | 112                             | 36                                | 5             | 55                              | 18                                | 0             | 39                        | 21                                | 1             |  |
| Levofloxacin                | 119                             | 76                                | 1             | 63                              | 82                                | 0             | 33                              | 40                                | 1             | 19                        | 39                                | 0             |  |
| Ofloxacin                   | 114                             | 67                                | 0             | 73                              | 70                                | 0             | 39                              | 29                                | 0             | 32                        | 27                                | 0             |  |
| Vancomycin                  | 106                             | 59                                | 0             | 136                             | 4                                 | 0             | 63                              | 6                                 | 0             | 58                        | 1                                 | 0             |  |
| Cefuroxime                  | 113                             | 17                                | 0             | 95                              | 3                                 | 0             | 52                              | 1                                 | 0             | 43                        | 2                                 | 0             |  |
| Amoxiclav                   | 123                             | 62                                | 18            | 115                             | 35                                | 1             | 63                              | 11                                | 0             | 49                        | 11                                | 0             |  |
| Clarithromycin              | 179                             | 27                                | 0             | 149                             | 3                                 | 0             | 72                              | 2                                 | 0             | 58                        | 3                                 | 0             |  |
| Ceftriaxone                 | 114                             | 44                                | 1             | 103                             | 12                                | 0             | 52                              | 7                                 | 50            | 38                        | 11                                | 0             |  |
| Moxifloxacin                | 86                              | 117                               | 3             | 80                              | 72                                | 0             | 39                              | 29                                | 0             | 30                        | 30                                | 1             |  |
| Amikacin                    | 129                             | 73                                | 1             | 93                              | 58                                | 0             | 38                              | 35                                | 0             | 32                        | 28                                | 0             |  |
| Cefepime                    | 158                             | 34                                | 0             | 124                             | 23                                | 0             | 66                              | 4                                 | 0             | 52                        | 9                                 | 0             |  |
| Lincomycin                  | 199                             | 4                                 | 0             | 151                             | 0                                 | 0             | 73                              | 0 92                              | 0             | 61                        | 0                                 | 0             |  |
| Gentamicin                  | 102                             | 90                                | 1             | 67                              | 77                                | 2             | 38                              | 35                                | 1             | 30                        | 28                                | 0             |  |
| Ciprofloxacin               | 60                              | 30                                | 1             | 85                              | 29                                | 3             | 17                              | 8                                 | 1             | 12                        | 19                                | 0             |  |
| Meropenem                   | 140                             | 56                                | 17            | 12                              | 58                                | 18            | 12                              | 31                                | 10            | 7                         | 25                                | 4             |  |
| Imipenem                    | 2                               | 18                                | 31            | 2                               | 22                                | 22            | 0                               | 13                                | 3             | 0                         | 12                                | 0             |  |
| Piperacillin-<br>Tazobactam | 59                              | 125                               | 12            | 33                              | 108                               | 0             | 30                              | 42                                | 0             | 23                        | 30                                | 1             |  |
| Piperacillin                | 47                              | 5                                 | 0             | 36                              | 0                                 | 0             | 12                              | 0                                 | 0             | 11                        | 0                                 | 0             |  |
| Trimethoprim                | 49                              | 5                                 | 0             | 41                              | 4                                 | 0             | 17                              | 0                                 | 0             | 15                        | 2                                 | 0             |  |
| Tetracycline                | 93                              | 21                                | 0             | 78                              | 12                                | 0             | 39                              | 6                                 | 0             | 35                        | 7                                 | 0             |  |
| Amoxycillin                 | 23                              | 0                                 | 0             | 16                              | 0                                 | 0             | 2                               | 0                                 | 0             | 15                        | 0                                 | 0             |  |
| penicillin                  | 23                              | 0                                 | 0             | 17                              | 0                                 | 0             | 3                               | 0                                 | 0             | 16                        | 0                                 | 0             |  |
| Cefadroxil                  | 18                              | 5                                 | 0             | 18                              | 0                                 | 0             | 3                               | 0                                 | 0             | 14                        | 1                                 | 0             |  |

| Volume 3     | irnal for Huma<br>5, Issue 1, June 202<br>/ shu.edu.ye |   | tiences |    |   | مجملة جامعة شبوة للعلوم الإنسانية والتطبيقية<br>المجلد الثالث، العدد الأول، يونيو 2025م، ص 297-305 |   |   |   |    |   |   |
|--------------|--|---|---------|----|---|--|---|---|---|----|---|---|
| Erythromycin | 22   | 0 | 0       | 17 | 0 | 0  | 3 | 0 | 0 | 16 | 0 | 0 |







#### Fig 2: Escherichia coli antibiotic sensitivity

**Discussion:** One of the major issues facing global public health in the twenty-first century is still AMR. If AMR is not sufficiently faced and dealt with properly, there could be severe consequences, including a return to the pre-antibiotic era, when common infections from childbirth, surgery, and open fractures could be fatal (Tang et al., 2023). To mitigate this

growing threat, robust surveillance systems and enhanced antimicrobial stewardship programs are urgently needed across both developed and developing nations (Ajulo & Awosile, 2024). A systematic review conducted by the Antimicrobial Resistance Collaborators highlighted alarming rates of resistance globally. They found Methicillin-resistant Staphylococcus aureus was 60-80% in Asia (except Russia), Africa, Eastern Mediterranean, Peru and Chile, while Third-generation cephalosporin-resistant Escherichia coli was 70-80% in Southeast Asia and the Persian Gulf and Fluoroquinolone-resistant *Escherichia coli* >80 in Yemen and Thailand, while Third-generation cephalosporin-resistant Klebsiella pneumoniae 70-80% in Balkan Peninsula, Russia, and Africa (Murray et al., 2022). Yahya A. Almutawif in Saudia Arabia found high resistance rates in uropathogens, the Gram-negative bacteria, to ampicillin (78.8%) and cephalexin (68.5%). Enterococcus spp., (> 62.3%) against ciprofloxacin, gentamicin, and tetracycline, while gram-positive Streptococcus spp. showed substantial resistance rates (> 76.6%) toward colistin and trimethoprim/ sulfamethoxazole (Almutawif & Eid, 2023). In the Eastern Mediterranean Region, 17.4%–79.6% for methicillin-resistant staphylococcus aureus, 28.2%-95.0% K. pneumoniae, and 32.6%-88.6% E. coli resistant to 3rd generation cephalosporin (Talaat et al., 2022).

Our study revealed even more concerning trends. Resistance rates soared to (89-100%) for several widely prescribed antibiotics including: Amoxycillin, penicillin, cefadroxil, erythromycin, Clarithromycin, Cefixime, Cefalexin, Cefuroxime, trimethoprim, Ceftriaxone, and Vancomycin. Imipenem emerged as the least resisted antibiotic, yet resistance still stood at 3.7%. These findings surpass previous reports from other governorates in Yemen like Aden 40-80 % (ALhlale et al., 2020; Almehdar et al., 2024; Badulla et al., 2020; Orubu et al., 2021), and Mukalla 37-70 % (Al-Haddad et al., 2010; Hameed, 2016), Sanaa 67-85% (Al-Yosaffi et al., 2023; Edrees & Anbar, 2021), and Taiz 45-85% (Al-Jendy et al., 2018). The prevalence of Staphylococcus aureus in vaginal swabs in our study was 43.6% which is similar to the study done in Iraq 44.4% and 44.3% (Mahmmod & AlHadban, 2022; Mohammad et al., 2024). These results raise a red flag and shed the light on a critical problem where 4 of the most common pathogenic bacteria were resistant to 11 of the most commonly prescribed antibiotics. Murray et al estimated 1.27 million preventable deaths were caused by drug-resistant bacteria worldwide in 2019, mainly due to Escherichia coli, Staphylococcus aureus, Klebsiella pneumoniae, Streptococcus pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa. WHO and other groups and researchers conclude that the spread of AMR is an urgent issue that needs a global, coordinated action plan to address. Information about the magnitude of the burden and trend of bacterial AMR in different parts of the world and the leading pathogens is mandatory. If left unchecked, AMR could make many bacterial pathogens spread and become much more lethal in the future (Murray et al., 2022). Great challenges in LMICs include a lack of an antimicrobial stewardship program, the availability of antibiotics over-the-counter, Self-Medication, the spread of counterfeit medications, with weak leadership and governance from health policy decision-makers (Alfadly et al., 2017; Almehdar et al., 2024). In an era of limited resources, LMICs are facing major problems that divert attention away from this pandemic, which is silently spreading, reaching not only the individual but also the society, the nation, and the entire global ecosystem (Sartelli et al., 2020).

**Conclusion and Recommendations:** Our study revealed that *Staphylococcus*, followed by *E. coli, Pseudomonas*, and *Klebsiella pneumoniae* were the most widespread pathogenic bacteria in several isolates. Alarmingly, the prevalence of antibiotic resistance is very high in Wadi Hadramout, and it seems to be higher than in other cities in Yemen, which needs immediate action by local health authorities.

There is a need for further studies about antibiotic abuse, self-medication, and microbiological surveillance, as well as an action plan by the health authority, mainly education at the local level to the general population and health workers community. For safe empirical antibiotic prescription, a regular study of antimicrobial resistance must be conducted.

#### Limitation

This study depends on the database of the laboratory with no direct contact with the patients or the laboratory techniques.

#### Acknowledgment

We sincerely thank Khobah Laboratories for their collaboration, which was crucial to the successful completion of this study. Their expertise and resources significantly facilitated our work on this research.

#### **References**:

- Abushaheen, M. A., Fatani, A. J., Alosaimi, M., Mansy, W., George, M., Acharya, S., Rathod, S., Divakar, D. D., Jhugroo, C., & Vellappally, S. (2020). Antimicrobial resistance, mechanisms and its clinical significance. Disease-a-Month, 66(6), 100971.
- Ajulo, S., & Awosile, B. (2024). Global antimicrobial resistance and use surveillance system (GLASS 2022): Investigating the relationship between antimicrobial resistance and antimicrobial consumption data across the participating countries. Plos one, 19(2), e0297921.
- Al-Haddad, A. M., Ghouth, A., & El-Hosseiny, M. (2010). Microbial resistance in patients with urinary tract infections in Al-Mukalla, Yemen. Sudan Journal of Medical Sciences, 5(2).
- Al-Jendy, A., Al-Ofairi, B., & Al-Ganady, M. (2018). Study of Pathogenic Bacterial Isolates from Patients with Skin Infections and their susceptibility to Antibiotics in Some Hospitals in Taiz City-Yemen. INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 1(2), 25-39.
- Al-Yosaffi, E. A., Al-Shamahy, H. A., Othman, A. M., Al-Haddad, A. M., & Al-Moyed, K. A. (2023). ANTIBIOTIC SENSITIVITY OF BACTERIAL BLOODSTREAM INFECTIONS IN THE INTENSIVE CARE UNIT PATIENTS OF UNIVERSITY HOSPITALS IN SANA'A CITY, YEMEN.
- Alfadly, S., Ballaswad, M. R., Amra, A. S., Alghadeer, S. M., Wajid, S., Al-Arifi, M. N., & Babelghaith, S. D. (2017). Self-medication with antibiotic amongst adults attending community pharmacies in Mukalla district, Yemen. Lat Am J Pharm, 36(2), 224-228.
- ALhlale, M. F., Humaid, A., Saleh, A. H., Alsweedi, K. S., & Edrees, W. H. (2020). Effect of most common antibiotics against bacteria isolated from surgical wounds in Aden Governorate hospitals, Yemen. Universal J Pharm Res, 5(1), 21-24.
- Almehdar, H., Yousef, N., van den Boogaard, W., Haider, A., Kanapathipillai, R., Al-Hodiani, E., Zelikova, E., Moh'd, W. G., Michel, J., & Malaeb, R. (2024). Antibiotic susceptibility patterns at the Médecins Sans Frontières (MSF) acute trauma hospital in Aden, Yemen: a retrospective study from January 2018 to June 2021. JAC-Antimicrobial Resistance, 6(2), dlae024.

- Almutawif, Y. A., & Eid, H. M. (2023). Prevalence and antimicrobial susceptibility pattern of bacterial uropathogens among adult patients in Madinah, Saudi Arabia. BMC Infectious Diseases, 23(1), 582.
- Badulla, W. F., Alshakka, M., & Mohamed Ibrahim, M. I. (2020). Antimicrobial resistance profiles for different isolates in Aden, Yemen: a cross-sectional study in a resource-poor setting. BioMed Research International, 2020.
- Baekkeskov, E., Rubin, O., Munkholm, L., & Zaman, W. (2020). Antimicrobial resistance as a global health crisis. In Oxford Research Encyclopedia of Politics.
- Balasubramanian, R., Van Boeckel, T. P., Carmeli, Y., Cosgrove, S., & Laxminarayan, R. (2023). Global incidence in hospital-associated infections resistant to antibiotics: An analysis of point prevalence surveys from 99 countries. PLoS medicine, 20(6), e1004178.
- Edrees, W. H., & Anbar, A. A. M. (2021). Prevalence and antibiotic susceptibility of Streptococcus pyogenes isolated from schoolchildren in Sana'a City, Yemen. PSM Veterinary Research, 6(2), 22-30.
- Hameed, E. A. B. (2016). Antimicrobial resistant patterns of pathogenic bacteria isolated from outpatients clinics in Mukalla, Hadhramout-Yemen. Sudan Journal of Medical Sciences, 11(2), 79-84.
- Ikuta, K. S., Swetschinski, L. R., Aguilar, G. R., Sharara, F., Mestrovic, T., Gray, A. P., Weaver, N. D., Wool, E. E., Han, C., & Hayoon, A. G. (2022). Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. The lancet, 400(10369), 2221-2248.
- Mahmmod, S. S., & AlHadban, W. G. (2022). Assessing the prevalence and antibiotic susceptibility patterns of S. aureus bacteria isolated from Iraqi women with vaginosis. Iraqi Journal of Science, 63(10), 4234-4240.
- Mohammad, S., Mohsen, A., & Jalil, I. (2024). Assessing the Prevalence of Bacterial Vaginosis among Infertile Women in Thi-Qar Province, Iraq. Infection Epidemiology and Microbiology, 10(4), 0-0.
- Murray, C. J., Ikuta, K. S., Sharara, F., Swetschinski, L., Aguilar, G. R., Gray, A., Han, C., Bisignano, C., Rao, P., & Wool, E. (2022). Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The lancet, 399(10325), 629-655.
- Orubu, E. S., Al-Dheeb, N., Ching, C., Jawdeh, S. B., Anderson, J., Sheikh, R., Hariri, F., Basaleem, H., & Zaman, M. H. (2021). Assessing antimicrobial resistance, utilization, and stewardship in Yemen: an exploratory mixed-methods study. The American Journal of Tropical Medicine and Hygiene, 105(5), 1404.
- Sartelli, M., C. Hardcastle, T., Catena, F., Chichom-Mefire, A., Coccolini, F., Dhingra, S., Haque, M., Hodonou, A., Iskandar, K., & Labricciosa, F. M. (2020). Antibiotic use in low and middleincome countries and the challenges of antimicrobial resistance in surgery. Antibiotics, 9(8), 497.
- Talaat, M., Zayed, B., Tolba, S., Abdou, E., Gomaa, M., Itani, D., Hutin, Y., & Hajjeh, R. (2022). Increasing Antimicrobial Resistance in World Health Organization Eastern Mediterranean Region, 2017-2019. Emerg Infect Dis, 28(4), 717-724. https://doi.org/10.3201/eid2804.211975
- Tang, K. W. K., Millar, B. C., & Moore, J. E. (2023). Antimicrobial Resistance (AMR). Br J Biomed Sci, 80, 11387. https://doi.org/10.3389/bjbs.2023.11387

الملخص

# مقاومة مضادات الميكروبات في وادي حضرموت: دراسة في مقاومة مضادات الميكروبات في وادي حضرموت: دراسة في مقاومة مدى

د. رويس محسن بن لكسر كلية الطب والعلوم الصحية، جامعة سيئون binlaksar2012@hotmail.com

أسماء بن حاتم

منوى الجابري منوى الجابري منوى الجابري منوى الجابري منوى الطب والعلوم الصحية، جامعة سيئون

معلومات البحث تاريخ الاستلام: 2025/01/22 تاريخ القبول: 2025/02/03

تاريخ النشر: 2025/07/08

الكلمات المفتاحية مقاومة المضادات الحيوية، البكتيريا، المكورات العنقودية الذهبية، الإشريكية القولونية، وادي حضرموت

الخلفية: مقاومة مضادات الميكروبات مشكلة عالمية تهدد الصحة العامة. تظهر أنماط مقاومة جديدة يوميًا تخترق الحدود الدولية وتنتشر بسرعة. اللهدف : تحديد انتشار مقاومة مضادات الميكروبات من العينات السريرية في وادي حضرموت المنهجية: دراسة مقطعية لتقدير انتشار مقاومة مضادات الميكروبات، وقد تم اختبار حساسية مضادات الميكروبات للزراعة الإيجابية بالطرق القياسية للزراعة والحساسية تجاه مضادات الميكروبات المختلفة. النتائج: إجمالي 552 عينة (مسحة مهبلية 197، فحص البول 142، مسحة جرح 124، وغيرها). كانت أكثر البكتيريا شيوعًا هي المكورات العنقودية الذهبية 206 (37.3٪) و الإشريكية القولونية (27.5٪) 152و الزائفة الزنجارية 74 (13.4٪) و كليبسيلا ((11.1٪).61 كان لدى المكورات العنقودية الذهبية مقاومة بنسبة 100٪ للأموكسيسيلين والبنسلين والإربثر وميسين بمتوسط مقاومة 72٪ لجميع المضادات الحيوبة المختبرة. كان لدى الإشريكية القولونية مقاومة بنسبة 100٪ للأموكسيسيلين والبنسلين والسيفادر وكسيل والإربثر وميسين و 94٪ لكلاريثر وميسين وسيفيكسيم وسيفاليكسين وسيفور وكسيم وتريميثوبريم وسيفترياكسون وفانكومايسين بمتوسط مقاومة 73٪ لجميع المضادات الحيوية المختبرة الاستنتاج : انتشار مقاومة المضادات الحيوية مرتفع جدًا في وادي حضرموت ويبدو أعلى من المدن الأخرى في اليمن.